Objective
Neurodegenerative diseases (NDDs) of aging are a growing burden on societies. Although studies on the degeneration of neurons have been a main focus of research, increasing evidence points to synapses as the site where Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) begin. There is growing evidence that synapses are sites of early and aberrant protein misfolding, aggregation and spread in NDDs. A key problem in research on NDDs has been that the normal physiological roles at synapses of the aggregation-prone proteins (β- amyloid/amyloid precursor protein, tau, α-synuclein and huntingtin), which are linked pathologically and genetically to these diseases, are not known. Using cutting-edge technologies and multidisciplinary approaches the SYNDEGEN consortium aims to bring together leading experts in cell biology, synapse biology and imaging, stem cell biology and NDDs in Europe to determine the molecular and cellular mechanisms whereby synapses become dysfunctional in AD, PD and HD for the purpose of developing novel therapies. The goal of the consortium is to train talented young scientists in interdisciplinary, innovative and collaborative research aimed at the development of novel molecular based treatment strategies for these major diseases of aging. A gap in the training of students in these important diseases is that disease expertise and novel methods to study synapses are localized in isolated groups in different locations in the EU. Similar questions are being asked about the mechanisms of synaptic dysfunction in AD, PD and HD, but no one university or company has sufficiently broad knowledge and technical expertise required to study and develop therapies for synaptic dysfunction in these disorders. This training programme will be implemented in 6 academic centres and 2 SMEs representing a comprehensive, highly interactive and multidisciplinary partnership.
Fields of science
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- medical and health sciencesbasic medicinephysiologypathophysiology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsprotein folding
- medical and health sciencesbasic medicineneurologyparkinson
Programme(s)
Funding Scheme
MSCA-ITN-ETN - European Training NetworksCoordinator
22100 Lund
Sweden
See on map
Participants (7)
CB2 1TN Cambridge
See on map
75794 Paris
See on map
37075 Goettingen
See on map
53127 Bonn
See on map
1015 Lausanne
See on map
Participation ended
17011 La Rochelle
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
901 85 Umea
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (6)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
2500 Valby
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
18119 Rostock
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
291 89 Kristianstad
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
Stockholm
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
89081 Ulm
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
901 87 Umea
See on map